Credit Industriel ET Commercial Purchases New Position in Grifols, S.A. (NASDAQ:GRFS)

Credit Industriel ET Commercial acquired a new position in Grifols, S.A. (NASDAQ:GRFS - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 609,855 shares of the biotechnology company's stock, valued at approximately $4,537,000. Grifols accounts for approximately 0.6% of Credit Industriel ET Commercial's portfolio, making the stock its 22nd largest holding. Credit Industriel ET Commercial owned about 0.09% of Grifols at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the company. Barclays PLC lifted its position in shares of Grifols by 381.2% in the third quarter. Barclays PLC now owns 592,552 shares of the biotechnology company's stock worth $5,261,000 after buying an additional 469,401 shares in the last quarter. Blue Trust Inc. lifted its position in shares of Grifols by 254.0% in the fourth quarter. Blue Trust Inc. now owns 6,927 shares of the biotechnology company's stock worth $52,000 after buying an additional 4,970 shares in the last quarter. Helikon Investments Ltd bought a new stake in Grifols during the fourth quarter worth approximately $580,000. R Squared Ltd bought a new position in shares of Grifols during the fourth quarter valued at approximately $28,000. Finally, China Universal Asset Management Co. Ltd. boosted its position in Grifols by 10.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 25,867 shares of the biotechnology company's stock valued at $192,000 after acquiring an additional 2,403 shares in the last quarter.

Grifols Stock Up 0.9%

Shares of Grifols stock traded up $0.08 during trading on Wednesday, reaching $8.31. The company's stock had a trading volume of 302,800 shares, compared to its average volume of 969,532. The company has a quick ratio of 0.79, a current ratio of 2.26 and a debt-to-equity ratio of 1.11. The company has a market cap of $5.71 billion, a price-to-earnings ratio of 7.10 and a beta of 0.44. Grifols, S.A. has a 1-year low of $5.79 and a 1-year high of $9.96. The company has a 50-day simple moving average of $7.31 and a two-hundred day simple moving average of $7.58.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on GRFS shares. Morgan Stanley started coverage on Grifols in a research report on Wednesday, February 12th. They set an "overweight" rating on the stock. Wall Street Zen raised Grifols from a "hold" rating to a "buy" rating in a research report on Friday, May 23rd.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.